|
|
Article: The Uganda Virus Research Institute (UVRI), in collaboration with the International AIDS Vaccine Initiative (IAVI) and Targeted Genetics, Launches HIV/AIDS Vaccine Trial in Entebbe, Uganda.
- Article from:
- Business Wire
- Article date:
- February 6, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SEATTLE & ENTEBBE, Uganda -- Targeted Genetics Corporation (Nasdaq:TGEN), The Uganda Virus Research Institute (UVRI), and the International AIDS Vaccine Initiative (IAVI), today announced the start of a Phase II clinical trial in Uganda to evaluate the safety and immunogenicity of tgAAC09, a preventive HIV/AIDS vaccine. This is the second IAVI-sponsored HIV vaccine trial to be conducted in Uganda.
The trial will be conducted at the Uganda Virus Research Institute (UVRI) in Entebbe, Uganda with Dr. Pontiano Kaleebu acting as the Principal Investigator. Parallel trials are currently underway at three sites in South Africa. There are also plans to evaluate the ...